What is Biofidelity?
Founded in 2019 in Cambridge, UK, Biofidelity is dedicated to enhancing access to superior cancer diagnostics. The company's core offering is a disruptive diagnostic technology platform designed to provide oncologists with clinically actionable data. This data is derived from the ultra-sensitive detection of markers crucial for cancer treatment guidelines, thereby enabling precise drug prescription at the optimal time. Biofidelity's platform is engineered for rapid, easy-to-interpret results, affordability, and seamless integration with existing laboratory infrastructure, facilitating broader adoption of high-quality cancer diagnostics.
How much funding has Biofidelity raised?
Biofidelity has raised a total of $66.5M across 3 funding rounds:
Unspecified
$6.5M
Series A
$36M
Other Financing Round
$24M
Unspecified (2017): $6.5M with participation from Longwall Ventures
Series A (2022): $36M led by Longwall Ventures, BlueYard Capital, and Agilent
Other Financing Round (2024): $24M supported by Octopus Ventures, Longwall Ventures, Agilent, and BlueYard Capital
Key Investors in Biofidelity
Longwall Ventures
Longwall Ventures is a venture capital firm that invests in early-stage deeptech businesses, particularly those leveraging UK scientific expertise to address global challenges. They focus on supporting innovative solutions from startups in the deeptech sector.
BlueYard Capital
BlueYard Capital is a venture capital firm investing in innovative technologies across computation, engineering, biology, and cryptocurrency, supporting founders building solutions for a better future.
Agilent
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, providing innovative laboratory solutions.
What's next for Biofidelity?
The substantial enterprise-level investment and recent strategic financing indicate Biofidelity is poised for significant scaling and market expansion. This capital infusion is expected to accelerate the development and commercialization of its advanced cancer diagnostic solutions, potentially solidifying its position in the competitive oncology market. The company's focus on affordability and accessibility suggests a strategy aimed at democratizing cancer diagnostics, making advanced screening and monitoring available to a wider patient population. Future growth will likely involve further technological refinement, strategic partnerships, and broader market penetration, leveraging its innovative platform to address unmet needs in cancer care.
See full Biofidelity company page
